• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Indaptus Therapeutics, Inc. (INDP) Stock Price, News & Analysis

Indaptus Therapeutics, Inc. (INDP) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.99

-$0.05

(-4.81%)

Day's range
$0.84
Day's range
$1.04
50-day range
$0.84
Day's range
$2.08
  • Country: US
  • ISIN: US45339J1051
52 wk range
$0.84
Day's range
$3.1


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -12.20
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (INDP)
  • Company Indaptus Therapeutics, Inc.
  • Price $0.99
  • Changes Percentage (-4.81%)
  • Change -$0.05
  • Day Low $0.84
  • Day High $1.04
  • Year High $3.10

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/12/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.77
  • Trailing P/E Ratio -1.5
  • Forward P/E Ratio -1.5
  • P/E Growth -1.5
  • Net Income $-15,423,471

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Indaptus Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of INDP in the last quarter?

    In the last quarter Indaptus Therapeutics, Inc. earnings were on Tuesday, November, 12th. The Indaptus Therapeutics, Inc. maker reported -$0.32 EPS for the quarter, beating analysts' consensus estimates of -$0.47 by $0.15.

  • What is the Indaptus Therapeutics, Inc. stock price today?

    Today's price of Indaptus Therapeutics, Inc. is $0.99 — it has decreased by -4.81% in the past 24 hours. Watch Indaptus Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Indaptus Therapeutics, Inc. release reports?

    Yes, you can track Indaptus Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Indaptus Therapeutics, Inc. stock forecast?

    Watch the Indaptus Therapeutics, Inc. chart and read a more detailed Indaptus Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Indaptus Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Indaptus Therapeutics, Inc. stock ticker.

  • How to buy Indaptus Therapeutics, Inc. stocks?

    Like other stocks, INDP shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Indaptus Therapeutics, Inc.'s EBITDA?

    Indaptus Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Indaptus Therapeutics, Inc.’s financial statements.

  • What is the Indaptus Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Indaptus Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Indaptus Therapeutics, Inc.'s financials relevant news, and technical analysis. Indaptus Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Indaptus Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Indaptus Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.